YAP1 and hepatocellular carcinoma: NUAK2 was shown to be required for tumourigenesis in a YAP1‐driven model of hepatocellular carcinoma, while a dual‐specific NUAK inhibitor suppressed growth of YAP1 overexpressing tumour xenografts [18].